IJPMBS 2026 Vol.15(4): 192-195
doi: 10.18178/ijpmbs.15.4.192-195
doi: 10.18178/ijpmbs.15.4.192-195
Dopamine Pathway Disorders in Adolescent ADHD and Core Targeted Therapeutic Strategies
Liu Yiran
Ulink Beijing High School, Beijing, China
Email: evieliu@126.com
Email: evieliu@126.com
Manuscript received September 24, 2026; accepted October 9, 2026; published November 17, 2026.
Abstract—Attention Deficit Hyperactivity Disorder (ADHD) is one of the most common neurodevelopmental disorders among adolescents worldwide. The growing disease burden of adolescent ADHD has attracted extensive academic attention. Cumulative empirical evidence identifies dopamine‑pathway dysfunction as the core biochemical mechanism underlying adolescent ADHD pathogenesis. Genetic and epigenetic regulatory processes jointly modulate these pathological alterations and drive disease progression. This review synthesizes recent studies published from 2021 to 2026, focusing on dopamine‑related molecular abnormalities, including elevated expression of the dopamine‑transporter protein encoded by the DAT1 gene and regulatory effects of DNA methylation on gene transcription. It further elaborates on the molecular mechanisms of action for two first‑line clinical medications targeting the dopaminergic system. Based on a comprehensive synthesis of existing literature, this review highlights key limitations in current research. Major drawbacks include over‑reliance on studies of isolated single‑neurotransmitter pathways and insufficient analysis of environmental risk factors such as prolonged exposure to short‑form digital media. This review proposes targeted directions for future research, including epigenetic‑biomarker‑based early‑screening approaches and individualized medication strategies tailored for adolescents. It establishes clearer logical links between basic molecular research and clinical practice, and provides theoretical support for future biological early‑intervention research on adolescent ADHD.
Keywords—adolescent Attention Deficit Hyperactivity Disorder (ADHD), dopamine pathway, Dopamine Transporter 1 (DAT1) gene, DNA methylation, targeted medication
Cite: Liu Yiran, "Dopamine Pathway Disorders in Adolescent ADHD and Core Targeted Therapeutic Strategies," International Journal of Pharma Medicine and Biological Sciences, Vol. 15, No. 4, pp. 192-195, 2026.
Copyright © 2026 by the authors. This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Keywords—adolescent Attention Deficit Hyperactivity Disorder (ADHD), dopamine pathway, Dopamine Transporter 1 (DAT1) gene, DNA methylation, targeted medication
Cite: Liu Yiran, "Dopamine Pathway Disorders in Adolescent ADHD and Core Targeted Therapeutic Strategies," International Journal of Pharma Medicine and Biological Sciences, Vol. 15, No. 4, pp. 192-195, 2026.
Copyright © 2026 by the authors. This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
